Blogs

Tirbanibulin shows how ADME science, dermal delivery, and topical formulation development turn skin drugs into real therapies. Read the full Syngene perspective now.

Explore how peptide conjugates are advancing veterinary oncology and pet therapeutics through targeted drug delivery. Discover emerging approaches today.

Explore how digital pathology is transforming predictive toxicology and safety assessment. Learn the latest approaches in modern toxicology—read more now.

How pharma teams balance speed and GXP compliance in outsourced R&D to deliver predictabletimelines and regulatory-ready outcomes. Explore the approach.

Eroom’s Law highlights a troubling trend in pharmaceutical R&D: the cost and time required to develop new drugs have been steadily increasing despite technological advances (1). As a result, drug discovery is under constant pressure.

Global pharmaceutical supply chains are under sustained pressure from rising regulatory expectations, complex molecules, and frequent disruptions across geographies. For manufacturers handling highly potent active pharmaceutical ingredients (HPAPIs), the challenge is more pronounced.

Cell line development is a critical early step in biologics manufacturing. For monoclonal antibodies and other therapeutic proteins, the quality of the master cell bank determines not only expression levels but also long-term process stability, regulatory confidence, and downstream scalability.

Integrated cell line development and biologics development are reshaping veterinary therapeutics. Discover how multi-modality innovation drives impact—read more today.

Understand antibody drug conjugate science, bioconjugation, and manufacturing controls that shape targeted therapy for cancer. Read the article today.

Tech transfer sounds like a handover, but in a CDMO, it is a stress test. A process that behaves in a bench hood can shift when it meets plant-scale mixing, utilities, sampling routines, and tighter execution windows.